Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: nokomis who wrote (79330)	1/18/2000 12:31:00 PM
From: Ron	Respond to of 120523

PHAR gets FDA OK for Heparin PharmaNetics Heparin Management Panel Approved by FDA RALEIGH, N.C.--(BW HealthWire)--January 18, 2000--PharmaNetics, Inc. (NASDAQ NM: PHAR - news), the holding company of Cardiovascular Diagnostics, Inc., today announced receipt of clearance from the Food and Drug Administration (FDA) to market the Company's Heparin Management Panel and Accent(TM) system. This system combines the innovative Thrombolytic Assessment System(TM) (TAS) technology and the currently marketed Heparin Management Test with two new test cards - the Heparin Titration Test(TM) and the Protamine Response Test(TM) along with the Accent, a hardware accessory to the TAS analyzer. The Accent is a microprocessor-based device that automatically calculates the information required by physicians to manage the anticoagulation of patients during cardiopulmonary bypass procedures. The TAS is currently marketed as Rapidpoint(TM) Coag by Bayer Diagnostics. The Heparin Management Panel and Accent system will be marketed by Bayer Diagnostics as Rapidpoint ACCENT with a launch anticipated in the second quarter. Commenting on the news of the FDA clearance, Fran Tuttle, Senior Vice President and General Manager, Critical Care Diagnostics, Bayer Corporation said, ``Coagulation is an important component of Bayer's critical care product menu to offer a complete diagnostic solution. These new products will add tremendous value to our critical care portfolio. Our investment in PharmaNetics was aimed at providing access to coagulation products that satisfy the increasing demand from physicians for timely access to diagnostic results.'